Inari Medical FY2027 EPS Estimate Reduced by Leerink Partnrs

Inari Medical, Inc. (NASDAQ:NARI) – Investment analysts at Leerink Partnrs dropped their FY2027 earnings per share (EPS) estimates for shares of Inari Medical in a research report issued to clients and investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the company will earn $0.54 per share for the year, down from their prior estimate of $0.56. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.77) per share. Leerink Partnrs also issued estimates for Inari Medical’s FY2028 earnings at $0.97 EPS.

NARI has been the topic of a number of other research reports. Leerink Partners began coverage on shares of Inari Medical in a report on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 target price on the stock. Stifel Nicolaus began coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They set a “hold” rating and a $50.00 price objective on the stock. Wells Fargo & Company cut their price objective on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Canaccord Genuity Group lifted their target price on shares of Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday, October 29th. Finally, Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $58.89.

Inari Medical Stock Down 0.4 %

NASDAQ NARI opened at $49.48 on Tuesday. The firm has a market capitalization of $2.90 billion, a PE ratio of -36.65 and a beta of 0.96. The stock’s 50 day moving average is $45.66 and its 200 day moving average is $47.33. Inari Medical has a twelve month low of $36.73 and a twelve month high of $67.13.

Hedge Funds Weigh In On Inari Medical

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vestal Point Capital LP increased its position in Inari Medical by 342.9% in the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock worth $63,922,000 after buying an additional 1,200,000 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in Inari Medical by 113.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock worth $71,324,000 after acquiring an additional 786,691 shares in the last quarter. Armistice Capital LLC increased its holdings in Inari Medical by 353.1% in the 2nd quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock worth $48,595,000 after acquiring an additional 786,501 shares in the last quarter. Jennison Associates LLC raised its stake in Inari Medical by 63.2% during the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock worth $65,021,000 after acquiring an additional 610,468 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Inari Medical by 11.1% during the first quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock valued at $268,681,000 after purchasing an additional 561,562 shares in the last quarter. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Inari Medical

In related news, Director William Hoffman sold 60,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $51.16, for a total value of $3,069,600.00. Following the transaction, the director now owns 501,233 shares of the company’s stock, valued at approximately $25,643,080.28. This trade represents a 10.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Mitch C. Hill sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total transaction of $135,390.00. Following the sale, the chief financial officer now directly owns 179,600 shares of the company’s stock, valued at approximately $8,105,348. This represents a 1.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 186,000 shares of company stock worth $8,990,990. Company insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.